Sunny Patel, MD
Rheumatology · Red Oak, TXNPI 1336583467
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $76,324 of the $100,091 with a category attached, or 76.3%. Amgen accounts for 82.0% of it on its own, with 30 other manufacturers making up the rest. 2025 is the largest year on record at $24,401, 9.7 times the $2,514 reported in 2019. Among rheumatology clinicians in TX with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,056 payments — averaging $94.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$82K
- UCB, Inc.$4K
- AbbVie$3K
- GSK$2K
- Mallinckrodt Hospital Products Inc.$1K
- Johnson & Johnson$1K
- plus $6K from 25 others
Across 72 payments — averaging $16,230 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$749K
- Janssen Research & Development, LLC$252K
- Novartis$126K
- Sanofi$37K
- UCB SA$5K
What the payments were for
- Consulting fees$3,6804%
- Speaking & faculty fees$76,32476%
- Grants$2400%
- Food & beverage$19,79120%
- Education$560%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen(2 entities) | 347 | $82,086 |
| UCB, Inc. | 80 | $4,347 |
| AbbVie | 118 | $2,823 |
| GSK | 69 | $2,092 |
| Mallinckrodt Hospital Products Inc. | 54 | $1,158 |
| Johnson & Johnson | 69 | $1,111 |
| E.r. Squibb & Sons, L.L.C. | 63 | $1,097 |
| AstraZeneca | 47 | $971 |
| Pfizer | 55 | $961 |
| ANI Pharmaceuticals, Inc. | 27 | $648 |
| Aurinia Pharma U.S., Inc. | 26 | $600 |
| Mallinckrodt Enterprises LLC | 13 | $411 |
| Novartis | 17 | $368 |
| Genentech USA, Inc. | 13 | $246 |
| Sanofi | 10 | $216 |
| Organon | 13 | $190 |
| Nevro Corp. | 2 | $173 |
| Fresenius Kabi USA, LLC | 7 | $126 |
| Boehringer Ingelheim | 5 | $100 |
| Lilly USA, LLC | 5 | $84 |
| Octapharma USA, Inc. | 2 | $50 |
| Ferring Pharmaceuticals Inc. | 2 | $40 |
| Hospira, Inc. | 2 | $31 |
| Bioventus LLC | 2 | $31 |
| Hikma Pharmaceuticals USA | 2 | $29 |
| Kiniksa Pharmaceuticals, Ltd. | 1 | $27 |
| Scilex Pharmaceuticals Inc. | 1 | $22 |
| Sandoz | 1 | $15 |
| Merck | 1 | $14 |
| AMAG Pharmaceuticals, Inc. | 1 | $13 |
| Ultragenyx Pharmaceutical Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$100,091 in reported general payments places this provider in the 90th percentile of 512 rheumatology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Humira(Cf) PenAdalimumab | 235 | $1,854,674 |
| RinvoqUpadacitinib | 126 | $847,732 |
| Enbrel SureclickEtanercept | 71 | $517,265 |
| Xeljanz XrTofacitinib Citrate | 32 | $183,290 |
| Orencia ClickjectAbatacept | 25 | $142,073 |
| Enbrel MiniEtanercept | 17 | $127,467 |
| Actemra ActpenTocilizumab | 41 | $121,138 |
| Taltz AutoinjectorIxekizumab | 15 | $104,266 |
| XeljanzTofacitinib Citrate | 11 | $62,351 |
| BenlystaBelimumab | 12 | $58,135 |
| KevzaraSarilumab | 11 | $48,021 |
| Hydroxychloroquine Sulfate | 213 | $6,486 |
| MethotrexateMethotrexate Sodium | 265 | $6,113 |
| Mycophenolate Mofetil | 48 | $5,091 |
| Leflunomide | 67 | $4,323 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRinvoq | $2,823 | $847,732126 claims |
| PfizerXeljanz | $961 | $62,35111 claims |
| GSKBenlysta | $2,092 | $58,13512 claims |
| SanofiKevzara | $216 | $48,02111 claims |
| Scilex Pharmaceuticals Inc.Colchicine | $22 | $45811 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 512 rheumatology providers in Texas.
Other rheumatology in Red Oak
- John CushDallas$3.7M
- Sanjay ChabraEl Paso$3.3M
- Dhiman BasuColleyville$1.8M
- Frank WellborneNew Braunfels$1.4M
- Christopher ParkerWest Lake Hills$1.4M
- Pendleton WickershamSan Antonio$954K
- Henry TownsendPlano$738K
- Zoran KurepaDallas$483K
- Giovanni GeslaniDallas$415K
- Dianne PetroneDallas$401K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.